Scarica l'app Stockscreener
17.76
6.35%
1.06
Dopo l'orario di chiusura:
18.11
0.35
+1.97%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.70
Aprire:
$16.39
Volume 24 ore:
1.11M
Relative Volume:
2.05
Capitalizzazione di mercato:
$404.72M
Reddito:
$59,000
Utile/perdita netta:
$-78.26M
Rapporto P/E:
-2.9132
EPS:
-6.0964
Flusso di cassa netto:
$-51.46M
1 W Prestazione:
+27.31%
1M Prestazione:
-1.22%
6M Prestazione:
+36.62%
1 anno Prestazione:
+150.85%
Intervallo 1D:
$16.07
$17.82
Intervallo di 1 settimana:
$13.49
$17.82
Portata 52W:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Nome
Avalo Therapeutics Inc
Settore
Industria
Telefono
410-522-8707
Indirizzo
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
17.76 | 404.72M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-05 | Iniziato | TD Cowen | Buy |
| 2025-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Jefferies | Buy |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-28 | Iniziato | Piper Sandler | Overweight |
| 2025-02-21 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-10-24 | Iniziato | H.C. Wainwright | Neutral |
| 2024-04-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
Avalo Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
AVTX Technical Analysis & Stock Price Forecast - Intellectia AI
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Sell Alert: Christopher Sullivan Sells Shares of Avalo T - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares - MarketBeat
Avalo Therapeutics CFO Sullivan sells $270k in stock - Investing.com
Avalo Therapeutics (AVTX) CMO Doyle Mittie sells $10,864 in stock - Investing.com
Avalo Therapeutics (AVTX) CFO executes Rule 10b5-1 stock sale plan - Stock Titan
Avalo Therapeutics (AVTX) CMO exercises options, sells 679 pre-planned shares - Stock Titan
Wall Street experts anticipate Avalo Therapeutics (AVTX) could surge by 113.34%: Key Insights You Need to Know - Bitget
Avalo Therapeutics, Inc. (AVTX) stock price, news, quote and history - Yahoo Finance Singapore
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know - Yahoo Finance
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,339 options - Stock Titan
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,370 vested options - Stock Titan
Logos Global (AVTX) discloses 1,285,000-share position, including options - Stock Titan
AVTX SEC FilingsAvalo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Avalo Therapeutics (AVTX) director acquires 3,166 shares via RSU vesting - Stock Titan
Avalo Therapeutics (AVTX) director exercises 3,166 RSUs, holds 6,333 shares - Stock Titan
Director at Avalo Therapeutics (AVTX) converts 3,166 RSUs to stock - Stock Titan
Avalo Therapeutics (AVTX) CEO exercises RSUs, shares withheld for taxes - Stock Titan
Avalo Therapeutics (AVTX) CFO nets shares from RSU vesting and tax settlement - Stock Titan
Director at Avalo Therapeutics (AVTX) exercises 3,166 RSUs into common stock - Stock Titan
Director at Avalo Therapeutics (AVTX) gains 3,166 common shares - Stock Titan
Growth Recap: Can Avalo Therapeutics Inc grow without external fundingMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
US Stocks Recap: Can Avalo Therapeutics Inc outperform under higher oil pricesMarket Sentiment Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to “Hold” at Wall Street Zen - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Volatility Watch: What analysts say about Avalo Therapeutics Inc stock2026 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
HC Wainwright Has Positive Outlook for AVTX Q1 Earnings - Defense World
Avalo Therapeutics' Jonathan Goldman and Mitchell Chan to Not Stand for Re-election - TradingView
Two Avalo Therapeutics (AVTX) directors to step down after 2026 meeting - stocktitan.net
Avalo Therapeutics, Inc. Announces Departure of Directors Dr. Jonathan Goldman and Mitchell Chan - marketscreener.com
HC Wainwright Issues Positive Outlook for AVTX Earnings - MarketBeat
Aug Macro: Is Avalo Therapeutics Inc a potential multi bagger2026 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $40.00 at HC Wainwright - Defense World
What date does Avalo Therapeutics's (AVTX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysis Recap: Is Avalo Therapeutics Inc in a bullish channel2026 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Avalo Therapeutics price target to $40 on trial confidence - au.investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
AVTX: HC Wainwright Raises Price Target, Maintains Buy Rating | - GuruFocus
H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Avalo Therapeutics 2025 Financial Review - AlphaStreet
Is Avalo Therapeutics Inc a potential multi bagger2026 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX St - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research - MarketBeat
Mizuho Securities Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Avalo Therapeutics Inc Azioni (AVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):